Platform Validation & Partnership Development
Oncology (Solid Tumors)
Key Facts
About SingleCell Biotechnology
SingleCell Biotechnology is an early-stage biotech with a platform technology focused on the most aggressive and treatment-resistant aspects of cancer. Its core innovation is a suite of assays that capture and analyze single cancer stem cells in states of dormancy, migration, and clonogenic growth, providing high-content imaging and downstream multi-omic profiling capabilities. The company, which licensed its foundational technology from UT Southwestern Medical Center, is pre-revenue and actively seeking partnerships with pharmaceutical and research organizations to apply its platform in drug screening and target identification, initially in glioblastoma and breast cancer. Its progress is supported by non-dilutive funding, including a grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
View full company profileTherapeutic Areas
Other Oncology (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-02 | Molecure | Phase I |
| ANXV | Annexin Pharmaceuticals | Preclinical |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| VEGF Kinoid | Neovacs | Preclinical |
| Undisclosed Preclinical Pipeline | OncoResponse | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Compound42 | Abbmira Therapeutics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| HRD Testing Solution | SeqOne Genomics | Commercial |